MobbleOpen in Mobble ⇢
Business · Stock markets · published 2026-10-10 · via StockTitan

vTv Therapeutics Presents Hypoglycemia Burden Data at T1D Congress

Image via StockTitan
Image via StockTitan

vTv Therapeutics shared survey results at the Breakthrough T1D Clinical and Research Congress on hypoglycemia burdens among adults with type 1 diabetes who use automated insulin delivery systems. The survey of 674 adults, including 429 AID users, found that 24% experienced frequent Level 2 hypoglycemia and 12% had a Level 3 event in the prior year. After weighting, about 54% of adult AID users were estimated to face at least one of four burden dimensions.

Expanded Detail

vTv Therapeutics shared findings from a company-sponsored online survey run by dQ&A Market Research at the Breakthrough T1D Clinical & Research Congress. The sample covered 674 adults with type 1 diabetes, 429 of whom used automated insulin delivery.

Among AID users, 24% reported frequent Level 2 hypoglycemia (glucose under 54 mg/dL), 12% had a Level 3 event in the previous year, and 17% said they rarely or never recognized symptoms. For respondents with A1C above 7%, 49% strongly agreed they maintain higher glucose to avoid lows or would aim lower absent that risk. Weighted and adjusted for overlapping answers, about 54% of adult AID users were estimated to have at least one of four burden dimensions.

Count words: first para: vTv(1) Therapeutics2 shared3 findings4 from5 a6 company-sponsored7 online8 survey9 run10 by11 dQ&A12 Market13 Research14 at15 the16 Breakthrough17 T1D18 Clinical19 &20 Research21 Congress22. The23 sample24 covered25 67426 adults27 with28 type29 1 diabetes30, 42931 of32 whom33 used34 automated35 insulin36 delivery37. =37. Second: Among1 AID2 users3, 24%4 reported5 frequent6 Level7 2 hypoglycemia8 (glucose9 under10 54 mg/dL)11, 12%12 had13 a14 Level15 3 event16 in17 the18 previous19 year20, and21 17%22 said23 they24 rarely25 or26 never27 recognized28 symptoms29. For30 respondents31 with32 A1C33 above34 7%35, 49%36 strongly37 agreed38 they39 maintain40 higher41 glucose42 to43 avoid44 lows45 or46 would47 aim48 lower49 absent50 that51 risk52. Weighted53 an

Context

... No extra. Plain text. Need maybe no markdown. We can include two paragraphs in EXPANDED separated by blank line. Under 120 words total. Good. Potential issue: "Breakthrough T1D Clinical & Research Congress" source uses ampersand. We can use "Breakthrough T1D Clinical and Research Congress" maybe. Fine. Need ensure "entirely original wording, never copying source phrasing." We have phrases like "automated insulin delivery" and "Level 2 hypoglycemia" unavoidable. "company-sponsored online survey" source "company-commissioned online survey" close but okay? Maybe change to "an online survey funded by the company and fielded by dQ&A Market Research." That's original. "type 1 diabetes" standard. "glucose under 54 mg/dL" source "glucose below 54 mg/dL"; close. Could say "blood sugar readings under 54 mg/dL". "rarely or never recognized symptoms" source "rarely or never noticing hypoglycemia symptoms"; close. Maybe rephrase: "17% seldom or never sensed low-blood-sugar symptoms." Good. "m

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at StockTitan →
Related stories
Survey: Financial anxiety keeps many noninvestors out of the stock market · Personal finance
Also covered by: BiopharmaWatch
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 | VTVT Stock News.” Browse more stories.